Wellington Management Group’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-249,635
| Closed | -$10M | – | 1932 |
|
|
2026
Q1 | $10M | Sell |
249,635
-12,471,717
| -98% | -$269M | ﹤0.01% | 1236 |
|
|
2025
Q4 | $320M | Buy |
12,721,352
+3,430,392
| +37% | +$80.5M | 0.06% | 284 |
|
|
2025
Q3 | $210M | Buy |
9,290,960
+313,998
| +3% | +$7.32M | 0.04% | 370 |
|
|
2025
Q2 | $155M | Sell |
8,976,962
-3,326,290
| -27% | -$61.6M | 0.03% | 418 |
|
|
2025
Q1 | $269M | Buy |
12,303,252
+502,403
| +4% | +$13.9M | 0.05% | 278 |
|
|
2024
Q4 | $377M | Sell |
11,800,849
-3,766,120
| -24% | -$113M | 0.07% | 230 |
|
|
2024
Q3 | $449M | Sell |
15,566,969
-821,728
| -5% | -$30.4M | 0.08% | 223 |
|
|
2024
Q2 | $629M | Buy |
16,388,697
+1,330,626
| +9% | +$60.3M | 0.11% | 179 |
|
|
2024
Q1 | $885M | Sell |
15,058,071
-1,387,219
| -8% | -$88.4M | 0.16% | 149 |
|
|
2023
Q4 | $984M | Buy |
16,445,290
+1,278,246
| +8% | +$64.8M | 0.18% | 132 |
|
|
2023
Q3 | $577M | Buy |
15,167,044
+8,502,769
| +128% | +$373M | 0.12% | 178 |
|
|
2023
Q2 | $607M | Sell |
6,664,275
-1,614,164
| -19% | -$139M | 0.12% | 178 |
|
|
2023
Q1 | $546M | Sell |
8,278,439
-479,222
| -5% | -$27.7M | 0.11% | 187 |
|
|
2022
Q4 | $453M | Sell |
8,757,661
-1,199,755
| -12% | -$63.6M | 0.09% | 212 |
|
|
2022
Q3 | $680M | Sell |
9,957,416
-1,585,327
| -14% | -$93.8M | 0.14% | 149 |
|
|
2022
Q2 | $522M | Sell |
11,542,743
-2,656,551
| -19% | -$121M | 0.11% | 186 |
|
|
2022
Q1 | $721M | Buy |
14,199,294
+1,868,641
| +15% | +$82.5M | 0.12% | 173 |
|
|
2021
Q4 | $583M | Buy |
12,330,653
+1,159,081
| +10% | +$45.6M | 0.09% | 207 |
|
|
2021
Q3 | $368M | Buy |
11,171,572
+457,747
| +4% | +$25.7M | 0.06% | 285 |
|
|
2021
Q2 | $677M | Buy |
10,713,825
+225,721
| +2% | +$11.6M | 0.11% | 186 |
|
|
2021
Q1 | $450M | Sell |
10,488,104
-20,007
| -0.2% | -$947K | 0.08% | 242 |
|
|
2020
Q4 | $601M | Buy |
10,508,111
+55,303
| +0.5% | +$2.34M | 0.11% | 190 |
|
|
2020
Q3 | $315M | Buy |
10,452,808
+8,297
| +0.1% | +$248K | 0.07% | 262 |
|
|
2020
Q2 | $341M | Buy |
10,444,511
+72,513
| +0.7% | +$2.33M | 0.08% | 228 |
|
|
2020
Q1 | $278M | Buy |
10,371,998
+6,054,734
| +140% | +$215M | 0.07% | 238 |
|
|
2019
Q4 | $132M | Buy |
4,317,264
+685,390
| +19% | +$19M | 0.03% | 498 |
|
|
2019
Q3 | $87.5M | Sell |
3,631,874
-1,513,433
| -29% | -$41.7M | 0.02% | 580 |
|
|
2019
Q2 | $130M | Buy |
5,145,307
+1,268,333
| +33% | +$25.8M | 0.03% | 491 |
|
|
2019
Q1 | $75.6M | Buy |
3,876,974
+3,861,326
| +24,676% | +$60.7M | 0.02% | 623 |
|
|
2018
Q4 | $206K | Buy |
+15,648
| New | +$240K | ﹤0.01% | 2007 |
|
Other funds holding APLS
Wellington Management Group's APLS Position: Q2 2026 in Review
Wellington Management Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 249,635 shares — an estimated $10M sold.
Wellington Management Group first reported a position in APLS in Q4 2018 and held it in 30 quarters. The position peaked at $984M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Wellington Management Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Wellington Management Group sold 249,635 Apellis Pharmaceuticals shares in Q2 2026, an estimated $10M.
- Wellington Management Group first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 30 quarters.
- Wellington Management Group's Apellis Pharmaceuticals position peaked at $984M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.